Hympavzi (Marstacimab)

Marstacimab binds specifically to coagulation factor XI, preventing its activation to factor XIa. This inhibition blocks the intrinsic pathway of the coagulation cascade, leading to reduced generation of thrombin and fibrin clot formation while preserving primary hemostasis, thereby lowering the risk of pathological thrombosis.

The dose of Hympavzi is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, renal function, and concomitant therapies. Dosing regimens are individualized and should follow the prescribing information provided by the clinician.

Safety of Hympavzi in pregnancy and lactation has not been established. The potential benefits must be weighed against unknown risks, and it should only be used if clearly needed and prescribed by a qualified healthcare provider.

To order Hympavzi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Unlike traditional anticoagulants that target thrombin or factor Xa, Hympavzi inhibits factor XI, a key component of the intrinsic pathway. This mechanism may offer a lower bleeding risk while still providing effective thrombosis prevention, positioning it as a potential alternative for patients where conventional anticoagulants pose higher hemorrhagic concerns.

Hympavzi should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Hympavzi is administered as a subcutaneous injection. The injection is typically performed by a healthcare professional in a clinical setting, following aseptic technique and the dosing schedule prescribed for the specific indication.

The most serious risks include major bleeding events such as gastrointestinal or intracranial hemorrhage, and rare hypersensitivity reactions that can manifest as anaphylaxis. Patients should be monitored closely for any signs of excessive bleeding or allergic response.

Hympavzi is contraindicated in patients with known hypersensitivity to Marstacimab or any excipients in the formulation. It should also be avoided in individuals with active major bleeding, uncontrolled severe hypertension, or those who are unable to comply with monitoring requirements.